February 9th 2023
Data from a retrospective study suggests that stereotactic body radiotherapy may be a suitable alternative to surgical resection for patients with primary lung neuroendocrine tumors, according to an expert from Moffitt Cancer Center.
Certain Factors Linked With Future Carcinoid Syndrome DiagnosisDecember 15th 2017
Patients with gastrointestinal neuroendocrine tumors with carcinoid syndrome are more than twice as likely to have certain pre-existing diagnoses compared with patients without carcinoid syndrome, according to the results of a study.
Proposed Liver Debulking Criteria for PNETs Could Improve SurvivalNovember 16th 2017
Researchers are proposing the consideration of expanding criteria for liver debulking in pancreatic neuroendocrine tumors to include a threshold of greater than 70% debulking, intermediate grade tumors, positive margins, parenchyma-sparing resections, and extrahepatic metastases.
Pancreatic Neuroendocrine Tumors: State-of-the-Art Diagnosis and ManagementOctober 15th 2017
In this review, we focus on the treatment of well-differentiated early and metastatic PNETs, emphasizing current controversies, recent advances in therapy, and the multidisciplinary approach required for optimal treatment.
QOL Analysis Supports Everolimus Use in Gastrointestinal, Lung NETsSeptember 10th 2017
Treatment of advanced, non-functional gastrointestinal or lung neuroendocrine tumors with everolimus resulted in improved progression-free survival with no relevant differences in health-related quality of life compared with placebo, according to an analysis of the RADIANT-4 trial.
Primary Metastatic Small Intestinal Carcinoid Tumor Without Carcinoid SyndromeOctober 15th 2015
Small intestinal “carcinoid” or well-differentiated grade 1 neuroendocrine tumors can have an insidious onset or be diagnosed serendipitously at the time of surgery, during the workup for another disorder, or during a screening test.
Small-Cell/Neuroendocrine Prostate Cancer: A Growing Threat?October 15th 2014
Treatment-emergent small-cell/neuroendocrine prostate cancer is likely to become of increasing clinical relevance in the era of widespread use of potent androgen receptor–targeted therapies.
Neuroendocrine (Small-Cell) Carcinomas: Why They Teach Us Essential Lessons About Prostate CancerOctober 15th 2014
Aggressive variants of prostate cancer often take the form of neuroendocrine or small-cell carcinomas, which frequently lack androgen receptor expression and respond poorly to hormonal therapies.